Maqbool Mudasir, Fekadu Ginenus, Jiang Xinchan, Bekele Firomsa, Tolossa Tadesse, Turi Ebisa, Fetensa Getahun, Fanta Korinan
Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar, 190006, Jammu and Kashmir, India.
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
Ann Med Surg (Lond). 2021 Nov 19;72:103077. doi: 10.1016/j.amsu.2021.103077. eCollection 2021 Dec.
The rising prevalence of osteoarthritis (OA) in the general population has necessitated the development of novel treatment options. It is critical to recognize the joint as a separate entity participating in degenerative processes, as well as the multifaceted nature of OA. OA is incurable because there is currently no medication that can stop or reverse cartilage or bone loss. As this point of view has attracted attention, more research is being directed toward determining how the various joint components are impacted and how they contribute to OA pathogenesis. Over the next few years, several prospective therapies focusing on inflammation, cartilage metabolism, subchondral bone remodelling, cellular senescence, and the peripheral nociceptive pathway are predicted to transform the OA therapy landscape. Stem cell therapies and the use of various biomaterials to target articular cartilage (AC) and osteochondral tissues are now being investigated in considerable detail. Currently, laboratory-made cartilage tissues are on the verge of being used in clinical settings. This review focuses on the update of clinical prospects and management of osteoarthritis, as well as future possibilities for the treatment of OA.
骨关节炎（OA）在普通人群中的患病率不断上升，这就需要开发新的治疗方法。认识到关节是参与退行性病变过程的独立实体以及OA的多方面性质至关重要。OA无法治愈，因为目前没有药物能够阻止或逆转软骨或骨质流失。随着这种观点受到关注，越来越多的研究致力于确定各种关节成分如何受到影响以及它们如何促成OA的发病机制。预计在未来几年，几种针对炎症、软骨代谢、软骨下骨重塑、细胞衰老和外周伤害感受途径的前瞻性疗法将改变OA的治疗格局。目前正在相当详细地研究干细胞疗法以及使用各种生物材料靶向关节软骨（AC）和骨软骨组织。目前，实验室制造的软骨组织即将用于临床。本综述重点介绍骨关节炎临床前景和管理的最新情况以及OA治疗的未来可能性。
